{
    "organizations": [],
    "uuid": "a8f5e38fe19abb6ae9a2c5e25c8d59ae9eac0f8d",
    "author": "",
    "url": "https://www.reuters.com/article/nabriva-study/nabrivas-pneumonia-drug-succeeds-in-late-stage-study-idUSL3N1SS3XF",
    "ord_in_thread": 0,
    "title": "Nabriva's pneumonia drug succeeds in late-stage study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21, 2018 / 11:38 AM / Updated 6 minutes ago Nabriva's pneumonia drug succeeds in late-stage study\nMay 21 (Reuters) - Nabriva Therapeutics Plc said on Monday its drug to treat adults suffering from a type of pneumonia met the main goal of a late-stage study.\nThe company plans to submit a marketing application for the drug, lefamulin, with the U.S. Food and Drug Administration in the fourth quarter of the year. (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar)",
    "published": "2018-05-21T14:36:00.000+03:00",
    "crawled": "2018-05-21T14:49:43.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "updated",
        "minute",
        "ago",
        "nabriva",
        "pneumonia",
        "drug",
        "succeeds",
        "study",
        "may",
        "reuters",
        "nabriva",
        "therapeutic",
        "plc",
        "said",
        "monday",
        "drug",
        "treat",
        "adult",
        "suffering",
        "type",
        "pneumonia",
        "met",
        "main",
        "goal",
        "study",
        "company",
        "plan",
        "submit",
        "marketing",
        "application",
        "drug",
        "lefamulin",
        "food",
        "drug",
        "administration",
        "fourth",
        "quarter",
        "year",
        "reporting",
        "manas",
        "mishra",
        "bengaluru",
        "editing",
        "sai",
        "sachin",
        "ravikumar"
    ]
}